Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sileishi Biotechnology is a China-based biopharmaceutical company specializing in the development of next-generation RNA therapeutics. The company focuses on messenger RNA (mRNA) and circular RNA (circRNA) technologies, supported by proprietary lipid nanoparticle (LNP) delivery platforms. Sileishi aims to address unmet medical needs in oncology, infectious diseases, and rare disorders. Led by industry veterans with extensive experience from global pharmaceutical firms like Merck KGaA, the company is advancing a pipeline of innovative RNA-based candidates through pre-clinical development. By optimizing the stability and translation efficiency of RNA molecules, Sileishi Biotechnology seeks to provide transformative treatments for patients worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sileishi Biotechnology.